Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

The New NCI Precision Medicine Trials. Clinical cancer research : an official journal of the American Association for Cancer Research Harris, L. N., Blanke, C. D., Erba, H. P., Ford, J. M., Gray, R. J., LeBlanc, M. L., Hu-Lieskovan, S., Litzow, M. R., Luger, S. M., Meric-Bernstam, F., O'Dwyer, P. J., Othus, M. K., Politi, K., Shepherd, L. E., Allegra, C. J., Chen, H. X., Ivy, S. P., Korde, L. A., Little, R. F., McShane, L. M., Moscow, J. A., Patton, D. R., Thurin, M., Yee, L. M., Doroshow, J. H. 2023

Abstract

Basket, umbrella, and platform trial designs (master protocols) have emerged over the last decade to study precision medicine approaches in oncology. First generation trials like NCI-MATCH have proven the principle that studying targeted therapies on a large scale is feasible both from the laboratory and clinical perspectives. However, single agent targeted therapies have shown limited ability to control metastatic disease, despite careful matching of drug to target. As such, newer approaches employing combinations of targeted therapy, or targeted therapy with standard therapies, need to be considered. The NCI has recently embarked on three 2nd generation precision medicine trials to address this need: ComboMATCH, iMATCH, and myeloMATCH. The design of these trials and necessary infrastructure are discussed in the following perspective.

View details for DOI 10.1158/1078-0432.CCR-23-0917

View details for PubMedID 37531248